Mylan's Methotrexate Sodium ANDA081235 Receives Abbreviated Approval
Mylan's ANDA081235 for Methotrexate Sodium has received an abbreviated approval from the FDA.
Published: July 20, 2026
Updated: July 20, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Chemotherapy
Company: Mylan
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Mylan
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Mylan's abbreviated approval for Methotrexate Sodium signifies increased competition in the oncology market, which could lead to pricing pressures and shifts in market share. This development is crucial for pharma strategy teams to assess competitive positioning and potential revenue impacts.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor Mylan's launch timeline and market uptake of Methotrexate Sodium.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.